TG Therapeutics (TGTX) Misses Q3 EPS by 19c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• Goldman Sachs sees refinery exemptions boosting DK cash flow
• Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities